Riccardo must now be aware how much of a backwater the ASX is when it comes to clinical biotechs. Despite the positive announcements of late RAD in retreat Had RAD been listed on the NASDAQ then the ASX would has most likely responded like a wagging tail of the US hound Want evidence of this just take a look at IMC after FDA hold was removed vol & SP up strongly on the NASDAQ listing, the ASX responds with modest gains.
RAD Price at posting:
15.5¢ Sentiment: None Disclosure: Held
